Peptide Reconstitution and Dose Calculator Important Disclaimer: This calculator is for informational purposes only and is NOT a substitute for professional medical advice
The SURMOUNT-1 trial (N=2,539), published in the New England Journal of Medicine in 2022 (DOI: 10.1056/NEJMoa2206038), evaluated tirzepatide at 5mg, 10mg, and 15mg weekly doses versus placebo in adults with obesity or overweight
Pachikian BD, Copine S, Suchareau M, Deldicque L
Before enrolling in LIV Body or any compounded GLP-1 program, ask the platform directly which compounding pathway your pharmacy uses, what its current legal status is, and how it's positioned for the regulatory environment ahead
If it froze, it's ruinedfull stop
4.6% in the non-GLP-1 group Significantly lower rates of acute myocardial infarction Lower risk of major adverse cardiac events overall Psoriatic arthritis already raises cardiovascular risk substantially